Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A

Comparison of Outcomes Between Low Dose Emicizumab and Extended Half-life Factor VIII With Pharmacokinetic-guided Prophylaxis in Clinically Severe Hemophilia A

• To outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration
• To study pharmacokinetic, side effect of low dose Emicizumab

• To compare outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration using ABR, AJBR and HJHS, HaemoQoL
• To study pharmacokinetic, side effect and effectiveness of low dose Emicizumab

Inclusion Criteria:

• Severe or moderate Hemophilia A with baseline FVIII:C of <3 IU/dl or severe bleeding phenotype
• Receiving low dose FVIII prophylaxis for at least 6 months

Exclusion Criteria:

• Detectable FVIII inhibitor at screening
• Detectable FVIII inhibitor at screening Having other underlying diseases: Juvenile rheumatoid arthritis, metabolic bone diseases, or other conditions mimicking or causing joint diseases